發(fā)布時(shí)間：2018-10-08 21:08

【摘要】：目的:研究過氧化物酶體增殖物激活受體-γ(peroxisome proliferator-activated receptor-γ,PPARγ)激動(dòng)劑吡格列酮(pioglitazone,P io)對(duì)動(dòng)脈粥樣硬化模型載脂蛋白E基因敲除(Apo E-/-)小鼠主動(dòng)脈中熱休克蛋白22(heat shock protein 22,HSP22)表達(dá)的影響,并探討HSP22在其中所起的作用。方法:1、36只8~9周齡Apo E-/-雄性小鼠,隨機(jī)分為4組:對(duì)照組(n=9,普通飼料),對(duì)照干預(yù)組(n=9,普通飼料+Pio),模型組(n=9,高脂飼料)與模型干預(yù)組(n=9,高脂飼料+Pio);對(duì)照組、對(duì)照干預(yù)組喂食普通飼料12周,模型組、模型干預(yù)組喂食高脂飼料12周,即高脂飲食(high-fat diet,HFD),其中干預(yù)組從第五周開始給予Pio(20mg/kg/d)干預(yù)處理,共干預(yù)8周。2、稱量各組小鼠每周體重;檢測(cè)各組小鼠基線及干預(yù)結(jié)束的血脂水平,包括:甘油三脂(triglyceride,TG)、總膽固醇(total cholesterol,TC)、高密度脂蛋白-膽固醇(high-density lipoprotein cholesterol,HDL-C)、低密度脂蛋白-膽固醇(low-density lipoprotein cholesterol,LDL-C);檢測(cè)干預(yù)結(jié)束時(shí)小鼠的空腹血糖。3、主動(dòng)脈整體油紅O染色及蘇木素-伊紅(hematoxylin and eosin,HE)染色法觀察各組小鼠動(dòng)脈粥樣硬化斑塊形成情況及病理學(xué)變化。4、免疫組化法檢測(cè)小鼠主動(dòng)脈HSP22表達(dá),Western Blot法檢測(cè)PPARγ、HSP22、細(xì)胞間粘附分子1(intercellular adhesio n molecule-1,ICAM-1)、內(nèi)皮型一氧化氮合酶(endothelial nitric oxide synthase,e NOS)、p-e NOS(ser1177)表達(dá),ELISA法檢測(cè)血清白細(xì)胞介素6(interleukin-6,IL-6)濃度。結(jié)果:1、血脂、血糖變化(1)基線血脂:各組Apo E-/-小鼠的基線血清TG、TC、HDL-C、LDL-C的水平無差異(P0.05);(2)干預(yù)結(jié)束時(shí)血脂:模型組和模型干預(yù)組小鼠血清TC、LDL-C較對(duì)照組及對(duì)照干預(yù)組明顯升高(P0.01),HDL-C顯著降低(P0.01),TG的變化無統(tǒng)計(jì)學(xué)意義。經(jīng)Pio干預(yù)后,模型干預(yù)組小鼠血清TC、LDL-C較模型組明顯降低(TC:P0.05,LDL-C:P0.01),HDL-C明顯升高(P0.01),TG的變化無統(tǒng)計(jì)學(xué)意義;對(duì)照干預(yù)組小鼠血清LDL-C較對(duì)照組顯著降低(P0.01),TG、TC、HDL-C無明顯變化。(3)干預(yù)結(jié)束時(shí)血糖:經(jīng)高脂飼料飼養(yǎng)后,模型組和模型干預(yù)組小鼠血糖較對(duì)照組及對(duì)照干預(yù)組明顯升高(P0.01);模型干預(yù)組較模型組無明顯變化。2、組織病理學(xué)觀察及分析(1)主動(dòng)脈整體油紅O染色:模型組和模型干預(yù)組小鼠主動(dòng)脈紅染脂質(zhì)斑塊多,其斑塊相對(duì)面積明顯高于對(duì)照組、對(duì)照干預(yù)組(P0.01),而模型干預(yù)組較模型組減少(P0.01);對(duì)照干預(yù)組較對(duì)照組有減少,但差異無統(tǒng)計(jì)學(xué)意義(P0.05)。(2)主動(dòng)脈根部HE染色:與對(duì)照組、對(duì)照干預(yù)組比較,模型組及模型干預(yù)組主動(dòng)脈根部可見大量動(dòng)脈粥樣硬化斑塊形成,其斑塊相對(duì)面積顯著增加(P0.01),與模型組比較,模型干預(yù)組斑塊面積減少(P0.01)。3、Western Blot法檢測(cè)主動(dòng)脈PPARγ蛋白的表達(dá)模型組主動(dòng)脈PPARγ的表達(dá)較對(duì)照組顯著升高(P0.01);而經(jīng)Pio治療后,模型干預(yù)組PPARγ的表達(dá)較模型組進(jìn)一步升高(P0.01),對(duì)照干預(yù)組PPARγ的表達(dá)較對(duì)照組進(jìn)一步升高(P0.01)。4、主動(dòng)脈HSP22蛋白的表達(dá)(1)Western Blot法:模型組及模型干預(yù)組主動(dòng)脈HSP22的表達(dá)較對(duì)照組、對(duì)照干預(yù)組顯著升高(P0.01);而模型干預(yù)組經(jīng)Pio治療后HSP22的表達(dá)較模型組降低(P0.01);(2)免疫組織化學(xué)法:對(duì)照組及對(duì)照干預(yù)組主動(dòng)脈內(nèi)棕色著色淺,HSP22表達(dá)量少;模型組主動(dòng)脈斑塊及血管壁棕色著色深,HSP22大量表達(dá);模型干預(yù)組與對(duì)照組相比,HSP22表達(dá)量也增加,但較模型組明顯較少;5、Western Blot法檢測(cè)主動(dòng)脈e NOS、p-e NOS蛋白的表達(dá)模型組主動(dòng)脈e NOS蛋白的表達(dá)較對(duì)照組、對(duì)照干預(yù)組顯著降低(P0.01),而模型干預(yù)組經(jīng)Pio干預(yù)后,e NOS的表達(dá)較模型組升高(P=0.027)。模型組主動(dòng)脈p-e NOS蛋白的表達(dá)較對(duì)照組降低(P=0.028)、較對(duì)照干預(yù)組顯著降低(P0.01);而模型干預(yù)組p-e NOS的表達(dá)較模型組顯著升高(P0.01)。6、Western Blot法檢測(cè)ICAM-1蛋白的表達(dá)模型組及模型干預(yù)組主動(dòng)脈ICAM-1的表達(dá)較對(duì)照組、對(duì)照干預(yù)組顯著升高(P0.01),給予Pio治療后模型干預(yù)組主動(dòng)脈ICAM-1的表達(dá)較高脂模型組降低(P0.01)。7、血清IL-6水平模型組血清IL-6的濃度較對(duì)照組、對(duì)照干預(yù)組顯著升高(P0.01),而給予Pio干預(yù)后,模型干預(yù)組血清IL-6的濃度較模型組降低(P0.01)。結(jié)論:1、高脂飲食可上調(diào)主動(dòng)脈PPARγ、HSP22的表達(dá),下調(diào)e NOS、p-e NOS的表達(dá),上調(diào)ICAM-1的表達(dá),促進(jìn)動(dòng)脈粥樣硬化形成。2、吡格列酮可激活PPARγ,下調(diào)主動(dòng)脈內(nèi)HSP22的表達(dá),上調(diào)e NOS、p-e NOS的表達(dá),下調(diào)ICAM-1的表達(dá),抑制動(dòng)脈粥樣硬化形成。
[Abstract]:AIM: To study the effects of pioglitazone (Pio) on the proliferation of peroxidases in the aorta of apolipoprotein E knockout mice (ApoE-/-) mice. HSP22 expression, and explore the role of HSP22 in it. Methods: 1, 36 male mice aged 8 to 9 weeks were randomly divided into 4 groups: control group (n = 9, normal feed), control intervention group (n = 9, normal feed + PIo), model group (n = 9, high fat feed) and model intervention group (n = 9, high fat feed + Pio); control group. In the control intervention group, 12 weeks of normal feed were fed, the model group and the model intervention group were fed with the high fat diet for 12 weeks, that is, the high-fat diet (HFD), among which the intervention group began to give PIo (20mg/ kg/ d) intervention treatment from the fifth week to intervene for 8 weeks. Serum lipids were detected at the end of baseline and intervention in each group, including triglyceride (TG), total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C); To detect the formation and pathological changes of atherosclerotic plaques in mice at the end of intervention, the formation and pathological changes of atherosclerotic plaques in mice were observed by the staining of whole oil red O and hematoxylin and eosin (HE) staining. The levels of interleukin-6 (IL-6) and interleukin-6 (IL-6) in serum were measured by Western blot. The expression of interleukin-6 (IL-6) was detected by ELISA. Results: There was no difference in serum TG, TC, HDL-C and LDL-C in the baseline serum TG, TC, HDL-C and LDL-C in all groups of Aso E-/-mice (P0.05). LDL-C was significantly higher than that in control group (P0.01), HDL-C decreased significantly (P <0.01), and TG had no statistical significance. After PIO intervention, the serum TC and LDL-C of the model intervention group were significantly lower than that in the model group (TC: P0.05, LDL-C: P0.01), HDL-C increased significantly (P <0.01), TG did not change significantly, and the serum LDL-C of the control group was significantly lower than that in the control group (P0.01), TG, TC and HDL-C had no obvious change. (3) At the end of the intervention, the blood glucose in the model group and the model intervention group was significantly higher than that in the control group (P0.01). Histopathological observation and analysis (1) The whole aorta oil red O staining: the model group and the model intervention group were significantly higher than the control group and the control intervention group (P0.01), while the model intervention group was lower than that in the model group (P0.01). There was no significant difference between control intervention group and control group (P0.05). (2) HE staining of the aortic root: Compared with the control group and the control intervention group, the model group and the model intervention group showed a large number of atherosclerotic plaques in the aortic root, and the relative area of the plaque increased significantly (P0.01). Compared with the model group, the plaque area of the model intervention group decreased (P0.01). Compared with the control group (P0.01), the expression of CD44v6 in the model intervention group was higher than that in the control group (P0.01). The expression of HSP22 in aorta and the expression of HSP22 in the model group and the model intervention group were significantly higher than that in the control group (P0.01). The expression of HSP22 in the model intervention group was lower than that of the model group (P0.01). In the control group and the control intervention group, the brown coloration of the aorta was shallow and the expression of HSP22 was small; the model group aortic plaque and blood vessel wall brown staining depth, HSP22 were expressed in large numbers; the model intervention group also increased the expression level of HSP22 compared with the control group, but the model group was less obvious; 5, The expression of NOS, p-e NOS protein in aorta was lower than that in control group (P = 0.01), and the expression of e NOS in the model group was higher than that in control group (P = 0. 01). The expression of p-e NOS protein in the model group was lower than that in the control group (P = 0.028), but the expression of p-e NOS in the model group was significantly higher than that in the control group (P0.01). The expression model of ICAM-1 and the expression of ICAM-1 in the model intervention group were higher than that in the control group (P0.01). The expression of ICAM-1 in the model intervention group was lower than that in the control group (P0.01). The serum IL-6 concentration in serum IL-6 group was higher than that in control group (P0.01), and the concentration of IL-6 in serum IL-6 group was lower than that in control group (P0.01). Conclusion: 1. High fat diet can upregulate the expression of ENOS, p-e NOS, regulate the expression of ICAM-1, regulate the expression of ICAM-1 and promote the formation of atherosclerosis. Down-regulates the expression of ICAM-1 and inhibits the formation of atherosclerosis.
【學(xué)位授予單位】：南昌大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R543.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 任黔川;彭芝蘭;譚欣;;PPARγ在卵巢漿液性囊腺癌中的表達(dá)[J];重慶醫(yī)學(xué);2009年23期

2 張乾勇;PPAR的結(jié)構(gòu)與功能及其生物學(xué)作用[J];國(guó)外醫(yī)學(xué)(衛(wèi)生學(xué)分冊(cè));2000年05期

3 白玉杰,牛丹,趙錦榮,張文紅,呂貫廷,閻小君;Rapid detection of PPAR_γ gene Pro12Ala polymorphism with fluorescence polarization in Chinese population[J];Journal of Medical Colleges of PLA;2003年03期

4 袁平戈;PPARα的主要功能是什么[J];中華肝臟病雜志;2003年05期

5 潘光棟;PPAR-γ及其配體在人體細(xì)胞的分子研究[J];職業(yè)衛(wèi)生與病傷;2003年02期

6 曹廷兵,葉治家,彭家和,鞏燕,黃剛;人PPARγ2 cDNA的克隆及其在大腸桿菌中的表達(dá)純化[J];第三軍醫(yī)大學(xué)學(xué)報(bào);2004年01期

7 王剛,陳繼俊,倪沛洲;PPARα受體亞型與新藥研究[J];藥學(xué)進(jìn)展;2004年01期

8 葉平;過氧化體增殖物激活型受體(PPAR)與心血管疾病[J];中華心血管病雜志;2004年07期

9 孫曙光,周智廣;PPARγ與1型糖尿病[J];國(guó)外醫(yī)學(xué).內(nèi)分泌學(xué)分冊(cè);2005年02期

10 胡桂芳,武革;PPARγ與2型糖尿病大血管病變的研究進(jìn)展[J];廣東醫(yī)學(xué)院學(xué)報(bào);2005年01期

相關(guān)會(huì)議論文 前10條

1 ;Genetic polymorphisms of PPAR-γ,HHEX,PTPRD,KCNQ1,and SRR affect therapeutic efficacy of Pioglitazone in Chinese Patients with type 2 diabetes[A];傳承與發(fā)展，，創(chuàng)湖南省生理科學(xué)事業(yè)的新高——湖南省生理科學(xué)會(huì)2011年度學(xué)術(shù)年會(huì)論文摘要匯編[C];2011年

2 ;Dynamic analysis and ligand binding affinity investigation of PPAR mutations[A];華東六省一市生物化學(xué)與分子生物學(xué)會(huì)2003年學(xué)術(shù)交流會(huì)論文摘要集[C];2003年

3 童南偉;;過氧化物酶增殖物激活受體(PPAR)a與脂質(zhì)代謝[A];全國(guó)首屆代謝綜合征的基礎(chǔ)與臨床專題學(xué)術(shù)會(huì)議論文匯編[C];2004年

4 王偉銘;章慧娣;劉峰;陳佳韻;陳楠;;PPARγ活化對(duì)腎間質(zhì)成纖維細(xì)胞的作用研究[A];2007年浙滬兩地腎臟病學(xué)術(shù)年會(huì)資料匯編[C];2007年

5 陳剛;林新富;梁繼興;林麗香;沈曉麗;;過氧化物酶體增殖物激活受體γ(PPARγ)基因多態(tài)性與老年男性骨質(zhì)疏松癥相關(guān)性研究[A];2008內(nèi)分泌代謝性疾病系列研討會(huì)暨中青年英文論壇論文匯編[C];2008年

6 陳剛;林新富;梁繼興;林麗香;沈曉麗;;過氧化物酶體增殖物激活受體γ(PPARγ)基因多態(tài)性與老年男性骨質(zhì)疏松癥相關(guān)性研究[A];2008中國(guó)醫(yī)師協(xié)會(huì)內(nèi)分泌代謝科醫(yī)師分會(huì)年會(huì)論文匯編[C];2008年

7 李潔;戴愛國(guó);胡瑞成;朱黎明;王梅芳;;PPARγ影響γ-谷氨酰半胱氨酸合成酶活性及表達(dá)在大鼠慢性阻塞性肺疾病中的作用[A];中國(guó)生理學(xué)會(huì)第23屆全國(guó)會(huì)員代表大會(huì)暨生理學(xué)學(xué)術(shù)大會(huì)論文摘要文集[C];2010年

8 管又飛;;脂質(zhì)過氧化物體增殖物激活受體γ(PPAR γ)與糖尿病腎病[A];中華醫(yī)學(xué)會(huì)腎臟學(xué)分會(huì)2004年年會(huì)暨第二屆全國(guó)中青年腎臟病學(xué)術(shù)會(huì)議專題講座匯編[C];2004年

9 孫莉;尚進(jìn)林;梁浩;程焱;;PPAR全激動(dòng)劑對(duì)小鼠局灶性腦缺血再灌注損傷的保護(hù)作用[A];第十一屆全國(guó)神經(jīng)病學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2008年

10 ;Endothelial PPARγmediates anti-inflammatory actions of rosiglitazone through dissociation of NF-κB[A];中國(guó)生理學(xué)會(huì)心血管生理學(xué)術(shù)研討會(huì)論文集[C];2011年

相關(guān)重要報(bào)紙文章 前3條

1 徐錚奎;發(fā)現(xiàn)PPAR拮抗劑[N];醫(yī)藥經(jīng)濟(jì)報(bào);2012年

2 曾凡新邋林敏;PPAR激動(dòng)劑類抗糖尿病藥研發(fā)喜憂參半[N];中國(guó)醫(yī)藥報(bào);2007年

3 袁松范;開發(fā)PPAR多通道激動(dòng)劑須謹(jǐn)慎[N];中國(guó)醫(yī)藥報(bào);2006年

相關(guān)博士學(xué)位論文 前10條

1 劉炳婷;SUMO特異性蛋白酶1調(diào)控脂肪形成的作用及分子機(jī)制[D];上海交通大學(xué);2014年

2 陳宏;巨噬細(xì)胞PPARγ對(duì)皮膚傷口愈合的作用研究[D];第三軍醫(yī)大學(xué);2015年

3 韓晶;PPARγ在腦缺血再灌注損傷和過氧化氫損傷中的調(diào)控機(jī)制研究[D];天津醫(yī)科大學(xué);2014年

4 張巖;PPARα/γ信號(hào)通路在高脂性脂肪性肝炎發(fā)病機(jī)制中的作用研究[D];蘇州大學(xué);2015年

5 張鷗;阿托伐他汀對(duì)動(dòng)脈粥樣硬化患者外周血中PPAR γ的作用研究及相關(guān)炎癥因子與動(dòng)脈粥樣硬化關(guān)系的建模分析[D];鄭州大學(xué);2016年

6 周毅;PPARγ介導(dǎo)的抗氧化機(jī)制在血管平滑肌細(xì)胞表型轉(zhuǎn)化中作用和機(jī)制研究[D];第三軍醫(yī)大學(xué);2016年

7 滕志朋;PPARβ/δ在大鼠蛛網(wǎng)膜下腔出血后早期腦損傷中的作用及其機(jī)制研究[D];重慶醫(yī)科大學(xué);2016年

8 佟強(qiáng);PPARβ/δ激活在帕金森病中的保護(hù)作用及機(jī)制研究[D];南京醫(yī)科大學(xué);2016年

9 王伶;高靜水壓刺激對(duì)血小板活化的影響及PPARγ的保護(hù)作用的研究[D];南昌大學(xué);2008年

10 孫晶;PPARγ1對(duì)系膜細(xì)胞外基質(zhì)生成的抑制作用及其機(jī)制[D];復(fù)旦大學(xué);2004年

相關(guān)碩士學(xué)位論文 前10條

1 曹智麗;過氧化物酶增殖物激活受體α（PPARα）在大鼠酒精性肝病發(fā)生過程中的變化[D];河北醫(yī)科大學(xué);2015年

2 宋石;miR-27a通過靶向調(diào)控PPARγ對(duì)酒精誘導(dǎo)大鼠BMSC分化的影響[D];鄭州大學(xué);2015年

3 鄒佳楠;PPAR-γ在IgA腎病發(fā)生中的作用及其機(jī)理研究[D];復(fù)旦大學(xué);2014年

4 陶曉燕;PPAR δ激動(dòng)劑和siRNA對(duì)大鼠骨髓基質(zhì)干細(xì)胞及成骨細(xì)胞分化和礦化的作用研究[D];安徽醫(yī)科大學(xué);2015年

5 于飛;新型PPARγ激動(dòng)劑對(duì)人腎癌細(xì)胞增殖抑制及其機(jī)制的研究[D];中國(guó)人民解放軍軍事醫(yī)學(xué)科學(xué)院;2015年

6 何修界;PPARγ激活對(duì)GDM小鼠胎盤脂肪酸運(yùn)輸?shù)鞍妆磉_(dá)水平的影響[D];安徽醫(yī)科大學(xué);2015年

7 魏璇;PPARγ通過對(duì)RUVBL2表達(dá)調(diào)控影響脂聯(lián)素分泌的研究[D];華中農(nóng)業(yè)大學(xué);2015年

8 游潔冰;PPARγ激動(dòng)劑、胰島素通過上調(diào)負(fù)性炎性因子TIPE2的表達(dá)抑制高糖、Aβ1-40引起的炎性反應(yīng)及神經(jīng)細(xì)胞調(diào)亡[D];山東大學(xué);2015年

9 劉常為;CTGF、COL-I、PPARγ在卵巢細(xì)胞外基質(zhì)的表達(dá)及與多囊卵巢綜合征的關(guān)系[D];暨南大學(xué);2015年

10 曹小潔;TLR4通過PPARγ下調(diào)ABCG1表達(dá)促進(jìn)血管平滑肌細(xì)胞內(nèi)炎癥反應(yīng)及脂質(zhì)沉積[D];第三軍醫(yī)大學(xué);2015年

本文編號(hào)：2258266